, Volume 68, Issue 1, pp 77–83 | Cite as

Subacute l-DOPA in mice: Biochemical and behavioural effects

  • O. Jenkins
  • R. Bailey
  • E. Crisp
  • D. M. Jackson
Original Investigations


Mice, pretreated orally with l-DOPA (200 mg/kg) plus benserazide (50 mg/kg) (l-DOPA-B) responded when challenged 24h later with the same drug combination, with significantly greater locomotor stimulation than animals pretreated with the vehicle. The enhanced response was not due to an intrinsic effect of benserazide. Nor was it dependent on a change in central dopamine (DA) receptor sensitivity, because the two pretreatment groups (l-DOPA-B and vehicle) did not differ in their locomotor response to a range of apomorphine doses (300–3,000 μg/kg, IP). The enhanced response was, however, due to DA receptor stimulation because it was antagonised by premedication of the mice with haloperidol or pimozide. Moreover, the enhanced response to l-DOPA-B challenge was also produced when mice were pretreated (24h earlier) with a high dose of l-DOPA alone (without benserazide) (1,200 mg/kg, orally). Animals which had been pretreated with l-DOPA-B had significantly higher brain levels of l-DOPA and DA after a subsequent challenge dose of l-DOPA-B administered 24h later. Thus the enhanced response to l-DOPA-B observed in the present experiment appears to be dependent on some mechanism which produces higher concentrations of l-DOPA (and consequently DA) in the brain.

Key words

l-DOPA Supersensitivity Subsensitivity Dopamine Locomotor activity 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Andén, N. E., Rubenson, A., Fuxe, K., Hökfelt, T.: Evidence for dopamine receptor stimulation by apomorphine. J. Pharm. Pharmacol. 19, 627–629 (1967)Google Scholar
  2. Andén, N. E., Engel, J., Rubenson, A.: Mode of action of l-DOPA on central noradrenaline mechanisms. Naunyn-Schmiedeberg's Arch. Pharmacol. 273, 1–10 (1972)Google Scholar
  3. Andén, N. E., Strömbom, U., Svensson, T. H.: Locomotor stimulation by l-DOPA: Relative importance of noradrenaline receptor activation. Psychopharmacology 54, 243–248 (1977)Google Scholar
  4. Atack, C. V.: The determination of dopamine by a modification of the trihydroxyindole fluorimetric assay. Br. J. Pharmacol. 48, 699–714 (1973)Google Scholar
  5. Atack, C., Magnusson, T.: A procedure for the isolation of noradrenaline (together with adrenaline), dopamine, 5-hydroxy-tryptamine and histamine from the same tissue sample using a single column of strongly acidic cation exchange resin. Acta Pharmacol. Toxicol. 42, 35–57 (1978)Google Scholar
  6. Bailey, R. C., Jackson, D. M.: A pharmacological study of changes in central nervous system receptor responsivness after long-term dexamphetamine and apomorphine administration. Psychopharmacology 56, 317–326 (1978)Google Scholar
  7. Bailey, R. C., Jackson, D. M., Bracs, P. U.: Long-term l-DOPA pretreatment of mice: Central receptor subsensitivity or supersensitivity. Psychopharmacology 66, 55–61 (1979)Google Scholar
  8. Barbeau, A., Mars, H., Gillo-Joffroy, L.: Adverse clinical side effects of levodopa therapy. In: Parkinson's disease, McDowell, F. H., Markham, C. H. (eds.), pp. 203–237. Philadelphia: Davis 1971Google Scholar
  9. Bartholini, G., Blum, J. E., Pletscher, A.: Dopa induced locomotor stimulation after inhibition of extracerebral decarboxylase. J. Pharm. Pharmacol. 21, 297–301 (1969)Google Scholar
  10. Bartholini, G., Pletscher, A.: Decarboxylase inhibitors. Pharmacol. Ther. B. 1, 407–421 (1975)Google Scholar
  11. Bianchine, J. R., Shaw, G. M.: Clinical pharmacokinetics of levodopa in Parkinson's disease. Clin. Pharmacokinetics 1, 313–338 (1976)Google Scholar
  12. Butcher, L. L., Engel, J.: Behavioural and biochemical effects of l-DOPA after peripheral decarboxylase inhibition. Brain Res. 15, 233–242 (1969)Google Scholar
  13. Coscia, C. J., Burke, W., Jamroz, G., Lasala, J. M., McFarlane, J., Mitchell, J., O'Toole, M. M., Wilson, M. L.: Occurrence of a new class of tetrahydroisoquinoline alkaloids in l-dopa-treated parkinsonian patients. Nature 269, 617–619 (1977)Google Scholar
  14. Dairman, W., Christenson, J. G., Udenfriend, S.: Deorease in liver aromatic l-amino-acid decarboxylase produced by chronic administration of l-DOPA. Proc. Natl. Acad. Sci. USA 68, 2117–2120 (1971)Google Scholar
  15. Dougan, D., Wade, D., Mearrick, P.: Agonist and antagonist effects of l-DOPA metabolites at a dopamine receptor suggest a pharmacological basis for the ‘on-off’ effect in Parkinson's disease. Nature 254, 70–71 (1975)Google Scholar
  16. Ernst, A. M.: Mode of action of apomorphine and dexamphetamine on gnawing compulsion in rats. Psychopharmacologia 10, 316–323 (1967)Google Scholar
  17. Kehr, W., Carlsson, A., Lindqvist, M.: A method for the determination of 3,4-dihydroxyphenylalanine (DOPA) in brain. Naunyn-Schmiedeberg's Arch. Pharmacol. 274, 273–280 (1972)Google Scholar
  18. Kehr, W., Lindqvist, M., Carlsson, A.: Distribution of dopamine in the rat cerebral cortex. J. Neural Trans. 38, 173–180 (1976)Google Scholar
  19. Klawans, H. L., Goetz, C., Nausieda, P. A., Weiner, W. J.: Levodopa-induced dopamine receptor hypersensitivity. Ann. Neurol. 2, 125–129 (1977)Google Scholar
  20. Klawans, H. L., Margolin, D. I.: Amphetamine-induced dopaminergic hypersensitivity in guinea pigs. Arch. Gen. Psychiatry. 32, 725–732 (1975)Google Scholar
  21. Sandler, M., Carter, S. B., Hunter, K. R., Stern, G. M.: Tetrahydroisoquinoline alkaloids: In vivo metabolites of l-DOPA in man. Nature 241, 439–443 (1973)Google Scholar
  22. Segal, D. S., Mandell, A. J.: Long-term administration of d-amphetamine: Progressive augmentation of motor activity and stereotypy. Pharmacol. Biochem. Behav. 2, 249–255 (1974)Google Scholar
  23. Sourkes, T. L.: Possible new metabolites mediating actions of l-DOPA. Nature 229, 413–414 (1971)Google Scholar
  24. Steel, R. G. D., Torrie, J. H.: Principles and procedures of statistics. New York: McGraw-Hill 1960Google Scholar
  25. Strömbom, U.: Catecholamine receptor agonists: Effects on motor activity and rate of tyrosine hydroxylation in mouse brain. Naunyn-Schmiedeberg's Arch. Pharmacol. 292, 167–176 (1976)Google Scholar

Copyright information

© Springer-Verlag 1980

Authors and Affiliations

  • O. Jenkins
    • 1
  • R. Bailey
    • 1
  • E. Crisp
    • 1
  • D. M. Jackson
    • 1
  1. 1.Department of PharmacologyThe University of SydneyAustralia

Personalised recommendations